HMGB1-Directed drug discovery targeting cutaneous inflammatory dysregulation

Current Drug Metabolism

Volumn 11, Issue 3, 2010, Pages 250-265

  Lamore, Sarah D ^a   Cabello, Christopher M ^a   Wondrak, Georg T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cutaneous pharmacotherapy; Cytokine; Drug discovery; HMGB1; Inflammation; Molecular target; RAGE; Skin

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR STIMULATING AGENT; ELECTROPHILE; G PROTEIN COUPLED RECEPTOR BLOCKING AGENT; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; SERINE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; RADIATION INJURY; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; SKIN INFECTION; SKIN INFLAMMATION; SOLAR RADIATION;

AMINO ACID SEQUENCE; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HMGB1 PROTEIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MOLECULAR SEQUENCE DATA; SIGNAL TRANSDUCTION; SKIN DISEASES;

EID: 77951703961     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920010791196337     Document Type: Review

References (156)

1. Goodwin, G.H.; Sanders, C.; Johns, E.W. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem., 1973, 38(1), 14-19.
2. Lotze, M.T.; Tracey, K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol., 2005, 5(4), 331-342.
3. Muller, S.; Ronfani, L.; Bianchi, M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med., 2004, 255(3), 332-343.
4. Ellerman, J.E.; Brown, C.K.; de Vera, M.; Zeh, H.J.; Billiar, T.; Rubartelli, A.; Lotze, M.T. Masquerader: high mobility group box-1 and cancer. Clin. Cancer Res., 2007, 13(10), 2836-2848.
5. Agresti, A.; Lupo, R.; Bianchi, M.E.; Muller, S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem. Biophys. Res. Commun., 2003, 302(2), 421-426. (Pubitemid 36397940)
6. Zayed, H.; Izsvak, Z.; Khare, D.; Heinemann, U.; Ivics, Z. The DNA-bending protein HMGB1 is a cellular cofactor of Sleeping Beauty transposition. Nucleic Acids Res., 2003, 31(9), 2313-2322. (Pubitemid 37442099)
7. Calogero, S.; Grassi, F.; Aguzzi, A.; Voigtlander, T.; Ferrier, P.; Ferrari, S.; Bianchi, M.E. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet., 1999, 22(3), 276-280.
8. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K.R.; Faist, E.; Abraham, E.; Andersson, J.; Andersson, U.; Molina, P.E.; Abumrad, N.N.; Sama, A.; Tracey, K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science, 1999, 285(5425), 248-251.
9. Wang, H.; Ward, M.F.; Sama, A.E. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock, 2009, 32(4), 348-357.
10. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.; Bianchi, M.E.; Nawroth, P.P.; Chavakis, T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J., 2007, 26(4), 1129-1139. (Pubitemid 46303578)
11. Hreggvidsdottir, H.S.; Ostberg, T.; Wahamaa, H.; Schierbeck, H.; Aveberger, A.C.; Klevenvall, L.; Palmblad, K.; Ottosson, L.; Andersson, U.; Harris, H.E. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol., 2009, 86(3), 655-662.
12. Dumitriu, I.E.; Bianchi, M.E.; Bacci, M.; Manfredi, A.A.; Rovere-Querini, P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol., 2007, 81(1), 84-91. (Pubitemid 46021256)
13. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Criollo, A.; Ortiz, C.; Lidereau, R.; Mariette, C.; Chaput, N.; Mira, J.P.; Delaloge, S.; Andre, F.; Tursz, T.; Kroemer, G.; Zitvogel, L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev., 2007, 220(47-59. (Pubitemid 350045573)
14. Ditsworth, D.; Zong, W.X.; Thompson, C.B. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the proinflammatory mediator HMGB1 from the nucleus. J. Biol. Chem., 2007, 282(24), 17845-17854.
15. Lim, S.C.; Choi, J.E.; Kim, C.H.; Duong, H.Q.; Jeong, G.A.; Kang, H.S.; Han, S.I. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int. J. Mol. Med., 2007, 20(2), 187-192.
16. Craven, R.R.; Gao, X.; Allen, I.C.; Gris, D.; Bubeck Wardenburg, J.; McElvania-Tekippe, E.; Ting, J.P.; Duncan, J.A. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One, 2009, 4(10), e7446.
17. Urbonaviciute, V.; Meister, S.; Furnrohr, B.G.; Frey, B.; Guckel, E.; Schett, G.; Herrmann, M.; Voll, R.E. Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis. Autoimmunity, 2009, 42(4), 305-307.
18. Gauley, J.; Pisetsky, D.S. The translocation of HMGB1 during cell activation and cell death. Autoimmunity, 2009, 42(4), 299-301.
19. Tsung, A.; Klune, J.R.; Zhang, X.; Jeyabalan, G.; Cao, Z.; Peng, X.; Stolz, D.B.; Geller, D.A.; Rosengart, M.R.; Billiar, T.R. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med., 2007, 204(12), 2913-2923.
20. Kawahara, K.; Hashiguchi, T.; Kikuchi, K.; Tancharoen, S.; Miura, N.; Ito, T.; Oyama, Y.; Nawa, Y.; Biswas, K.K.; Meng, X.; Morimoto, Y.; Shrestha, B.; Sameshima, H.; Maruyama, I. Induction of high mobility group box 1 release from serotonin-stimulated human umbilical vein endothelial cells. Int. J. Mol. Med., 2008, 22(5), 639-644.
21. Feghali, K.; Iwasaki, K.; Tanaka, K.; Komaki, M.; Machigashira, M.; Ishikawa, I.; Izumi, Y. Human gingival fibroblasts release high-mobility group box-1 protein through active and passive pathways. Oral Microbiol. Immunol., 2009, 24(4), 292-298.
22. Chen, K.; Huang, J.; Gong, W.; Iribarren, P.; Dunlop, N.M.; Wang, J.M. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol., 2007, 7(10), 1271-1285. (Pubitemid 47126372)
23. van Zoelen, M.A.; Yang, H.; Florquin, S.; Meijers, J.C.; Akira, S.; Arnold, B.; Nawroth, P.P.; Bierhaus, A.; Tracey, K.J.; van der Poll, T. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock, 2009, 31(3), 280-284.
24. Park, J.S.; Svetkauskaite, D.; He, Q.; Kim, J.Y.; Strassheim, D.; Ishizaka, A.; Abraham, E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem., 2004, 279(9), 7370-7377. (Pubitemid 38294612)
25. Curtin, J.F.; Liu, N.; Candolfi, M.; Xiong, W.; Assi, H.; Yagiz, K.; Edwards, M.R.; Michelsen, K.S.; Kroeger, K.M.; Liu, C.; Muhammad, A.K.; Clark, M.C.; Arditi, M.; Comin-Anduix, B.; Ribas, A.; Lowenstein, P.R.; Castro, M.G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med., 2009, 6(1), e10.
26. Lebre, M.C.; van der Aar, A.M.; van Baarsen, L.; van Capel, T.M.; Schuitemaker, J.H.; Kapsenberg, M.L.; de Jong, E.C. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol., 2007, 127(2), 331-341. (Pubitemid 46106911)
27. Lai, Y.; Gallo, R.L. Toll-like receptors in skin infections and inflammatory diseases. Infect. Disord. Drug Targets, 2008, 8(3), 144-155.
28. Niebuhr, M.; Lutat, C.; Sigel, S.; Werfel, T. Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. Allergy, 2009, 64(11), 1580-1587.
29. Ballanger, F.; Tenaud, I.; Volteau, C.; Khammari, A.; Dreno, B. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch. Dermatol. Res., 2008, 300(5), 215-223.
30. Rauvala, H.; Rouhiainen, A. RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr. Mol. Med., 2007, 7(8), 725-734.
31. Ramasamy, R.; Yan, S.F.; Schmidt, A.M. RAGE: therapeutic target and biomarker of the inflammatory response - the evidence mounts. J. Leukoc. Biol., 2009, 86(3), 505-512.
32. Wolf, R.; Howard, O.M.; Dong, H.F.; Voscopoulos, C.; Boeshans, K.; Winston, J.; Divi, R.; Gunsior, M.; Goldsmith, P.; Ahvazi, B.; Chavakis, T.; Oppenheim, J.J.; Yuspa, S.H. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol., 2008, 181(2), 1499-1506.
33. Bopp, C.; Bierhaus, A.; Hofer, S.; Bouchon, A.; Nawroth, P.P.; Martin, E.; Weigand, M.A. Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care, 2008, 12(1), 201.
34. Yan, S.F.; Ramasamy, R.; Schmidt, A.M. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J. Mol. Med., 2009, 87(3), 235-247.
35. Rojas, A.; Figueroa, H.; Morales, E. Fueling inflammation at tumor microenvironment: the role of multiligand/rage axis. Carcinogenesis, 2010, 31(3), 334-341
36. Schmidt, A.M.; Sahagan, B.; Nelson, R.B.; Selmer, J.; Rothlein, R.; Bell, J.M. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr. Opin. Investig. Drugs, 2009, 10(7), 672-680.
37. Luan, Z.G.; Zhang, H.; Yang, P.T.; Ma, X.C.; Zhang, C.; Guo, R.X. HMGB1 activates nuclear factor-kappaB signaling by RAGE and increases the production of TNF-alpha in human umbilical vein endothelial cells. Immunobiology, 2010, 17(4), 666-676
38. Abe, R.; Shimizu, T.; Sugawara, H.; Watanabe, H.; Nakamura, H.; Choei, H.; Sasaki, N.; Yamagishi, S.; Takeuchi, M.; Shimizu, H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J. Invest. Dermatol., 2004, 122(2), 461-467. (Pubitemid 38281070)
39. Kang, R.; Tang, D.; Schapiro, N.E.; Livesey, K.M.; Farkas, A.; Loughran, P.; Bierhaus, A.; Lotze, M.T.; Zeh, H.J. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ, 2010, 17(4), 666-676
40. Sparvero, L.J.; Asafu-Adjei, D.; Kang, R.; Tang, D.; Amin, N.; Im, J.; Rutledge, R.; Lin, B.; Amoscato, A.A.; Zeh, H.J.; Lotze, M.T. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med., 2009, 7, 17.
41. Lohwasser, C.; Neureiter, D.; Weigle, B.; Kirchner, T.; Schuppan, D. The receptor for advanced glycation end products is highly expressed in the skin and upregulated by advanced glycation end products and tumor necrosis factor-alpha. J. Invest. Dermatol., 2006, 126(2), 291-299. (Pubitemid 43323163)
42. Huttunen, H.J.; Fages, C.; Kuja-Panula, J.; Ridley, A.J.; Rauvala, H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res., 2002, 62(16), 4805-4811.
43. Wondrak, G.T.; Jacobson, M.K.; Jacobson, E.L. An Emerging Molecular Target in Melanoma: Cellular Carbonyl Stress and the Inhibition of Mitochondrial Survival Pathways by Carbonyl Scavenger Agents. Curr. Cancer Ther. Rev., 2005, 1, 271-276.
44. Gebhardt, C.; Riehl, A.; Durchdewald, M.; Nemeth, J.; Furstenberger, G.; Muller-Decker, K.; Enk, A.; Arnold, B.; Bierhaus, A.; Nawroth, P.P.; Hess, J.; Angel, P. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med., 2008, 205(2), 275-285. (Pubitemid 351281593)
45. Zimmermann, K.; Volkel, D.; Pable, S.; Lindner, T.; Kramberger, F.; Bahrami, S.; Scheiflinger, F. Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation, 2004, 28(4), 221-229. (Pubitemid 41449422)
46. Gong, Q.; Xu, J.F.; Yin, H.; Liu, S.F.; Duan, L.H.; Bian, Z.L. Protective effect of antagonist of high-mobility group box 1 on lipopolysaccharide-induced acute lung injury in mice. Scand. J. Immunol., 2009, 69(1), 29-35.
47. Li, J.; Kokkola, R.; Tabibzadeh, S.; Yang, R.; Ochani, M.; Qiang, X.; Harris, H.E.; Czura, C.J.; Wang, H.; Ulloa, L.; Wang, H.; Warren, H.S.; Moldawer, L.L.; Fink, M.P.; Andersson, U.; Tracey, K.J.; Yang, H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med., 2003, 9(1-2), 37-45. (Pubitemid 36667690)
48. Yang, H.; Ochani, M.; Li, J.; Qiang, X.; Tanovic, M.; Harris, H.E.; Susarla, S.M.; Ulloa, L.; Wang, H.; DiRaimo, R.; Czura, C.J.; Wang, H.; Roth, J.; Warren, H.S.; Fink, M.P.; Fenton, M.J.; Andersson, U.; Tracey, K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA, 2004, 101(1), 296-301.
49. Youn, J.H.; Shin, J.S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol., 2006, 177(11), 7889-7897.
50. Ito, I.; Fukazawa, J.; Yoshida, M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem., 2007, 282(22), 16336-16344. (Pubitemid 47100350)
51. Kazama, H.; Ricci, J.E.; Herndon, J.M.; Hoppe, G.; Green, D.R.; Ferguson, T.A. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity, 2008, 29(1), 21-32.
52. Bonaldi, T.; Talamo, F.; Scaffidi, P.; Ferrera, D.; Porto, A.; Bachi, A.; Rubartelli, A.; Agresti, A.; Bianchi, M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J., 2003, 22(20), 5551-5560.
53. Oh, Y.J.; Youn, J.H.; Ji, Y.; Lee, S.E.; Lim, K.J.; Choi, J.E.; Shin, J.S. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol., 2009, 182(9), 5800-5809.
54. Ulloa, L.; Batliwalla, F.M.; Andersson, U.; Gregersen, P.K.; Tracey, K.J. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum., 2003, 48(4), 876-881. (Pubitemid 36418228)
55. Mantell, L.L.; Parrish, W.R.; Ulloa, L. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Shock, 2006, 25(1), 4-11. (Pubitemid 43755979)
56. Yang, H.; Tracey, K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta, 2009, 1799(1-2), 149-156.
57. Zhu, S.; Li, W.; Ward, M.F.; Sama, A.E.; Wang, H. High Mobility Group Box 1 Protein as a Potential Drug Target for Infection- and Injury-Elicited Inflammation. Inflamm. Allergy Drug Targets, 2010, 9(1), 60-72.
58. Pan, H.F.; Wu, G.C.; Li, W.P.; Li, X.P.; Ye, D.Q. High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus. Mol. Biol. Rep., 2010, 37(3), 1191-1195.
59. Haberman, A.B. Strategies to Move Beyond Target Validation. Genet. Eng. News, 2005, 25(21), 36-37.
60. Chuong, C.M.; Nickoloff, B.J.; Elias, P.M.; Goldsmith, L.A.; Macher, E.; Maderson, P.A.; Sundberg, J.P.; Tagami, H.; Plonka, P.M.; Thestrup-Pederson, K.; Bernard, B.A.; Schroder, J.M.; Dotto, P.; Chang, C.M.; Williams, M.L.; Feingold, K.R.; King, L.E.; Kligman, A.M.; Rees, J.L.; Christophers, E. What is the 'true' function of skin? Exp. Dermatol., 2002, 11(2), 159-187.
61. Wondrak, G.T. Let the sun shine in: mechanisms and potential for therapeutics in skin photodamage. Curr. Opin. Investig. Drugs, 2007, 8(5), 390-400.
62. Baudouin, C.; Charveron, M.; Tarroux, R.; Gall, Y. Environmental pollutants and skin cancer. Cell Biol. Toxicol., 2002, 18(5), 341-348.
63. Bause, S.M.; Lamore, S.D.; Wondrak, G.T. More than skin deep: the human skin tissue equivalent as an advanced drug discovery tool. Front. Drug Des. Discov., 2009, 4, 135-161.
64. Wondrak, G.T.; Jacobson, M.K.; Jacobson, E.L. Endogenous UVA-photosensitizers: mediators of skin photodamage and novel targets for skin photoprotection. Photochem. Photobiol. Sci., 2006, 5(2), 215-237.
65. Marchini, G.; Hultenby, K.; Nelson, A.; Yektaei-Karin, E.; Stabi, B.; Lonne-Rahm, S.; Ulfgren, A.K.; Brismar, H. Increased expression of HMGB-1 in the skin lesions of erythema toxicum. Pediatr. Dermatol., 2007, 24(5), 474-482. (Pubitemid 47631923)
66. Ayer, L.M.; Senecal, J.L.; Martin, L.; Dixon, G.H.; Fritzler, M.J. Antibodies to high mobility group proteins in systemic sclerosis. J. Rheumatol., 1994, 21(11), 2071-2075.
67. Rosenberg, A.M.; Cordeiro, D.M. Relationship between sex and antibodies to high mobility group proteins 1 and 2 in juvenile idiopathic arthritis. J. Rheumatol., 2000, 27(10), 2489-2493.
68. Yoshizaki, A.; Komura, K.; Iwata, Y.; Ogawa, F.; Hara, T.; Muroi, E.; Takenaka, M.; Shimizu, K.; Hasegawa, M.; Fujimoto, M.; Sato, S. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin. Immunol., 2009, 29(2), 180-189.
69. Davies, C.A.; Herrick, A.L.; Cordingley, L.; Freemont, A.J.; Jeziorska, M. Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. Rheumatology (Oxford), 2009, 48(8), 876-882.
70. Popovic, K.; Ek, M.; Espinosa, A.; Padyukov, L.; Harris, H.E.; Wahren-Herlenius, M.; Nyberg, F. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum., 2005, 52(11), 3639-3645. (Pubitemid 41612235)
71. Barkauskaite, V.; Ek, M.; Popovic, K.; Harris, H.E.; Wahren-Herlenius, M.; Nyberg, F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus, 2007, 16(10), 794-802. (Pubitemid 350069792)
72. Scheinfeld, N.; Deleo, V.A. Photosensitivity in lupus erythematosus. Photodermatol. Photoimmunol. Photomed., 2004, 20(5), 272-279.
73. Reich, A.; Meurer, M.; Viehweg, A.; Muller, D.J. Narrow-band UVB-induced externalization of selected nuclear antigens in keratinocytes: implications for lupus erythematosus pathogenesis. Photochem. Photobiol., 2009, 85(1), 1-7.
74. Abeyama, K.; Stern, D.M.; Ito, Y.; Kawahara, K.; Yoshimoto, Y.; Tanaka, M.; Uchimura, T.; Ida, N.; Yamazaki, Y.; Yamada, S.; Yamamoto, Y.; Yamamoto, H.; Iino, S.; Taniguchi, N.; Maruyama, I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest., 2005, 115(5), 1267-1274. (Pubitemid 40629045)
75. Singer, A.J.; McClain, S.A.; Taira, B.R.; Guerriero, J.L.; Zong, W. Apoptosis and necrosis in the ischemic zone adjacent to third degree burns. Acad. Emerg. Med., 2008, 15(6), 549-554.
76. McNamara, A.R.; Zamba, K.D.; Sokolich, J.C.; Jaskille, A.D.; Light, T.D.; Griffin, M.A.; Meyerholz, D.K. Apoptosis is Differentially Regulated by Burn Severity and Dermal Location. J. Surg. Res., 2009. [Epub ahead of print]
77. Limana, F.; Germani, A.; Zacheo, A.; Kajstura, J.; Di Carlo, A.; Borsellino, G.; Leoni, O.; Palumbo, R.; Battistini, L.; Rastaldo, R.; Muller, S.; Pompilio, G.; Anversa, P.; Bianchi, M.E.; Capogrossi, M.C. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ. Res., 2005, 97(8), e73-83.
78. Germani, A.; Limana, F.; Capogrossi, M.C. Pivotal advances: high-mobility group box 1 protein - a cytokine with a role in cardiac repair. J. Leukoc. Biol., 2007, 81(1), 41-45.
79. Ranzato, E.; Patrone, M.; Pedrazzi, M.; Burlando, B. HMGb1 promotes scratch wound closure of HaCaT keratinocytes via ERK1/2 activation. Mol. Cell Biochem., 2009, 332(1-2), 199-205.
80. Rong, L.L.; Gooch, C.; Szabolcs, M.; Herold, K.C.; Lalla, E.; Hays, A.P.; Yan, S.F.; Yan, S.S.; Schmidt, A.M. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor. Neurol. Neurosci., 2005, 23(5-6), 355-365.
81. Straino, S.; Di Carlo, A.; Mangoni, A.; De Mori, R.; Guerra, L.; Maurelli, R.; Panacchia, L.; Di Giacomo, F.; Palumbo, R.; Di Campli, C.; Uccioli, L.; Biglioli, P.; Bianchi, M.E.; Capogrossi, M.C.; Germani, A. High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J. Invest. Dermatol., 2008, 128(6), 1545-1553. (Pubitemid 351693201)
82. Ochoa, O.; Torres, F.M.; Shireman, P.K. Chemokines and diabetic wound healing. Vascular, 2007, 15(6), 350-355.
83. Palumbo, R.; Sampaolesi, M.; De Marchis, F.; Tonlorenzi, R.; Colombetti, S.; Mondino, A.; Cossu, G.; Bianchi, M.E. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol., 2004, 164(3), 441-449.
84. Poser, I.; Golob, M.; Buettner, R.; Bosserhoff, A.K. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol. Cell Biol., 2003, 23(8), 2991-2998.
85. Sharma, A.; Ray, R.; Rajeswari, M.R. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest., 2008, 26(8), 843-851.
86. Hao, Q.; Du, X.Q.; Fu, X.; Tian, J. Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma. Zhonghua Zhong Liu Za Zhi, 2008, 30(4), 292-295.
87. Sasahira, T.; Kirita, T.; Oue, N.; Bhawal, U.K.; Yamamoto, K.; Fujii, K.; Ohmori, H.; Luo, Y.; Yasui, W.; Bosserhoff, A.K.; Kuniyasu, H. High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci., 2008, 99(9), 1806-1812.
88. Sheng, X.; Du, X.; Zhang, X.; Li, D.; Lu, C.; Li, Q.; Ma, Z.; Song, Q.; Wang, C. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat. Med. J., 2009, 50(5), 455-464.
89. Marr, D.G.; Poser, I.; Shellman, Y.G.; Bosserhoff, A.K.; Norris, D.A. Ultraviolet radiation induces release of MIA: a new mechanism for UVR-induced progression of melanoma. Int. J. Oncol., 2004, 25(1), 105-111.
90. Jachimczak, P.; Apfel, R.; Bosserhoff, A.K.; Fabel, K.; Hau, P.; Tschertner, I.; Wise, P.; Schlingensiepen, K.H.; Schuler-Thurner, B.; Bogdahn, U. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques. Int. J. Cancer, 2005, 113(1), 88-92. (Pubitemid 39507314)
91. Mollica, L.; De Marchis, F.; Spitaleri, A.; Dallacosta, C.; Pennacchini, D.; Zamai, M.; Agresti, A.; Trisciuoglio, L.; Musco, G.; Bianchi, M.E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol., 2007, 14(4), 431-441.
92. Pavlov, V.A.; Ochani, M.; Yang, L.H.; Gallowitsch-Puerta, M.; Ochani, K.; Lin, X.; Levi, J.; Parrish, W.R.; Rosas-Ballina, M.; Czura, C.J.; Larosa, G.J.; Miller, E.J.; Tracey, K.J.; Al-Abed, Y. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med., 2007, 35(4), 1139-1144. (Pubitemid 46598966)
93. Freedman, R.; Olincy, A.; Buchanan, R.W.; Harris, J.G.; Gold, J.M.; Johnson, L.; Allensworth, D.; Guzman-Bonilla, A.; Clement, B.; Ball, M.P.; Kutnick, J.; Pender, V.; Martin, L.F.; Stevens, K.E.; Wagner, B.D.; Zerbe, G.O.; Soti, F.; Kem, W.R. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry, 2008, 165(8), 1040-1047.
94. Taniguchi, N.; Kawahara, K.; Yone, K.; Hashiguchi, T.; Yamakuchi, M.; Goto, M.; Inoue, K.; Yamada, S.; Ijiri, K.; Matsunaga, S.; Nakajima, T.; Komiya, S.; Maruyama, I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum., 2003, 48(4), 971-981. (Pubitemid 36418239)
95. Hagiwara, S.; Iwasaka, H.; Goto, K.; Ochi, Y.; Mizunaga, S.; Saikawa, T.; Noguchi, T. Recombinant thrombomodulin prevents heat stroke by inhibition of high mobility group box 1 protein in sera of rats. Shock, 2010, [Epub ahead of print].
96. Ito, T.; Kawahara, K.; Okamoto, K.; Yamada, S.; Yasuda, M.; Imaizumi, H.; Nawa, Y.; Meng, X.; Shrestha, B.; Hashiguchi, T.; Maruyama, I. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb. Vasc. Biol., 2008, 28(10), 1825-1830. (Pubitemid 351588112)
97. Chorny, A.; Anderson, P.; Gonzalez-Rey, E.; Delgado, M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol., 2008, 180(12), 8369-8377.
98. Onoue, S.; Misaka, S.; Yamada, S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(4-6), 579-590.
99. Sheriff, S.; Joshi, R.; Friend, L.A.; James, J.H.; Balasubramaniam, A. Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides, 2009, 30(10), 1909-1913.
100. Chen, Y.; Akirav, E.M.; Chen, W.; Henegariu, O.; Moser, B.; Desai, D.; Shen, J.M.; Webster, J.C.; Andrews, R.C.; Mjalli, A.M.; Rothlein, R.; Schmidt, A.M.; Clynes, R.; Herold, K.C. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol., 2008, 181(6), 4272-4278.
101. Herczenik, E.; Gebbink, M.F. Molecular and cellular aspects of protein misfolding and disease. FASEB J., 2008, 22(7), 2115-2133.
102. Papadavid, E.; Stratigos, A.J.; Falagas, M.E. Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer. Expert Opin. Pharmacother., 2007, 8(11), 1743-1755. (Pubitemid 47296552)
103. Kim, H.M.; Park, B.S.; Kim, J.I.; Kim, S.E.; Lee, J.; Oh, S.C.; Enkhbayar, P.; Matsushima, N.; Lee, H.; Yoo, O.J.; Lee, J.O. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell, 2007, 130(5), 906-917.
104. Tidswell, M.; Tillis, W.; Larosa, S.P.; Lynn, M.; Wittek, A.E.; Kao, R.; Wheeler, J.; Gogate, J.; Opal, S.M. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med., 2010, 38(1), 72-83.
105. Sun, Y.; Pearlman, E. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Invest. Ophthalmol. Vis. Sci., 2009, 50(3), 1247-1254.
106. Asl, M.N.; Hosseinzadeh, H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother. Res., 2008, 22(6), 709-724. (Pubitemid 351955567)
107. Sakamoto, R.; Okano, M.; Takena, H.; Ohtsuki, K. Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro. Biol. Pharm. Bull., 2001, 24(8), 906-911. (Pubitemid 32750316)
108. Kato, H.; Kanaoka, M.; Yano, S.; Kobayashi, M. 3- Monoglucuronyl- glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J. Clin. Endocrinol. Metab., 1995, 80(6), 1929-1933.
109. Wang, S.; Zhu, W.; Ou, S.; Guan, Y.; Chen, L.; Yang, M. Effects of penetration enhancers on in vitro percutaneous absorption and amount retained in skin of paeonol, dictamnine, fraxinellone and glycyrrhetinic acid in Liangfu cream. Zhongguo Zhong Yao Za. Zhi., 2009, 34(14), 1778-1782.
110. Rahman, S.; Sultana, S. Glycyrrhizin exhibits potential chemopreventive activity on 12-O-tetradecanoyl phorbol-13-acetate-induced cutaneous oxidative stress and tumor promotion in Swiss albino mice. J. Enzyme Inhib. Med. Chem., 2007, 22(3), 363-369. (Pubitemid 47225729)
111. Tracey, K.J. Reflex control of immunity. Nat. Rev. Immunol., 2009, 9(6), 418-428.
112. Huston, J.M.; Gallowitsch-Puerta, M.; Ochani, M.; Ochani, K.; Yuan, R.; Rosas-Ballina, M.; Ashok, M.; Goldstein, R.S.; Chavan, S.; Pavlov, V.A.; Metz, C.N.; Yang, H.; Czura, C.J.; Wang, H.; Tracey, K.J. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med., 2007, 35(12), 2762-2768.
113. Wang, H.; Liao, H.; Ochani, M.; Justiniani, M.; Lin, X.; Yang, L.; Al-Abed, Y.; Wang, H.; Metz, C.; Miller, E.J.; Tracey, K.J.; Ulloa, L. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med., 2004, 10(11), 1216-1221. (Pubitemid 39540438)
114. van Maanen, M.A.; Lebre, M.C.; van der Poll, T.; LaRosa, G.J.; Elbaum, D.; Vervoordeldonk, M.J.; Tak, P.P. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum., 2009, 60(1), 114-122.
115. Gu, R.X.; Gu, H.; Xie, Z.Y.; Wang, J.F.; Arias, H.R.; Wei, D.Q.; Chou, K.C. Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor. Med. Chem., 2009, 5(3), 250-262.
116. Rosas-Ballina, M.; Goldstein, R.S.; Gallowitsch-Puerta, M.; Yang, L.; Valdes-Ferrer, S.I.; Patel, N.B.; Chavan, S.; Al-Abed, Y.; Yang, H.; Tracey, K.J. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol. Med., 2009, 15(7-8), 195-202.
117. Osborne-Hereford, A.V.; Rogers, S.W.; Gahring, L.C. Neuronal nicotinic alpha7 receptors modulate inflammatory cytokine production in the skin following ultraviolet radiation. J. Neuroimmunol., 2008, 193(1-2), 130-139.
118. Mills, C.M.; Hill, S.A.; Marks, R. Transdermal nicotine suppresses cutaneous inflammation. Arch. Dermatol., 1997, 133(7), 823-825. (Pubitemid 27337540)
119. Chen, G.; Li, J.; Qiang, X.; Czura, C.J.; Ochani, M.; Ochani, K.; Ulloa, L.; Yang, H.; Tracey, K.J.; Wang, P.; Sama, A.E.; Wang, H. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J. Lipid Res., 2005, 46(4), 623-627. (Pubitemid 43073271)
120. Coughlin, S.R.; Camerer, E. PARticipation in inflammation. J. Clin. Invest., 2003, 111(1), 25-27.
121. Lo, C.J.; Fu, M.; Kim, B. Macrophage TNF mRNA expression is modulated by protease inhibitors. J. Surg. Res., 1997, 69(2), 408-412. (Pubitemid 27317890)
122. Pelagotti, F.; Cecchi, M.; Messori, A. Use of gabexate mesylate in Italian hospitals: a multicentre observational study. J. Clin. Pharm. Ther., 2003, 28(3), 191-196. (Pubitemid 36783096)
123. Yuksel, M.; Okajima, K.; Uchiba, M.; Okabe, H. Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes. J. Pharmacol. Exp. Ther., 2003, 305(1), 298-305. (Pubitemid 36373864)
124. Bianchi, M.; Ulrich, P.; Bloom, O.; Meistrell, M., 3rd; Zimmerman, G.A.; Schmidtmayerova, H.; Bukrinsky, M.; Donnelley, T.; Bucala, R.; Sherry, B. An inhibitor of macrophage arginine transport and nitric oxide production (CNI-1493) prevents acute inflammation and endotoxin lethality. Mol. Med., 1995, 1(3), 254-266.
125. Hidaka, S.; Iwasaka, H.; Hagiwara, S.; Noguchi, T. Gabexate Mesilate Inhibits the Expression of HMGB1 in Lipopolysaccharide-Induced Acute Lung Injury. J. Surg. Res., 2009, [Epub ahead of print] (Pubitemid 46692008)
126. Hagiwara, S.; Iwasaka, H.; Togo, K.; Noguchi, T. A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1. Inflammation, 2008, 31(4), 227-234.
127. Hagiwara, S.; Iwasaka, H.; Hidaka, S.; Hasegawa, A.; Noguchi, T. Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm. Res., 2009, 58(4), 198-203.
128. Nakae, H.; Tajimi, K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther. Apher. Dial., 2003, 7(5), 483-485. (Pubitemid 37370008)
129. Hagiwara, S.; Iwasaka, H.; Noguchi, T. Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury. J. Anesth., 2007, 21(2), 164-170. (Pubitemid 46692008)
130. Hagiwara, S.; Iwasaka, H.; Matumoto, S.; Noguchi, T. Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7. Shock, 2007, 27(4), 429-435. (Pubitemid 46594976)
131. Ui, H.; Andoh, T.; Lee, J.B.; Nojima, H.; Kuraishi, Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur. J. Pharmacol., 2006, 530(1-2), 172-178. (Pubitemid 43037138)
132. Kiyohara, Y.; Komada, F.; Iwakawa, S.; Fuwa, T.; Okumura, K. Systemic effects of epidermal growth factor (EGF) ointment containing protease inhibitor or gelatin in rats with burns or open wounds. Biol. Pharm. Bull., 1993, 16(1), 73-76. (Pubitemid 23121753)
133. Fink, M.P. Ethyl pyruvate: a novel treatment for sepsis. Novartis Found Symp., 2007, 280, 147-156; discussion 156-164.
134. Fink, M.P. Ethyl pyruvate: a novel anti-inflammatory agent. J. Intern. Med., 2007, 261(4), 349-362. (Pubitemid 46474763)
135. Ulloa, L.; Ochani, M.; Yang, H.; Tanovic, M.; Halperin, D.; Yang, R.; Czura, C.J.; Fink, M.P.; Tracey, K.J. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA, 2002, 99(19), 12351-12356.
136. Jacobson, E.L.; Kim, H.; Kim, M.; Wondrak, G.T.; Jacobson, M.K. In: Developing Topical Prodrugs for Skin Cancer Prevention; Alberts, Ed.; Springer: Berlin, 2005; pp. 139-160.
137. Sappington, P.L.; Cruz, R.J., Jr.; Harada, T.; Yang, R.; Han, Y.; Englert, J.A.; Ajami, A.A.; Killeen, M.E.; Delude, R.L.; Fink, M.P. The ethyl pyruvate analogues, diethyl oxaloproprionate, 2-acetamidoacrylate, and methyl-2-acetamidoacrylate, exhibit antiinflammatory properties in vivo and/or in vitro. Biochem. Pharmacol., 2005, 70(11), 1579-1592.
138. Song, M.; Kellum, J.A.; Kaldas, H.; Fink, M.P. Evidence that glutathione depletion is a mechanism responsible for the antiinflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J. Pharmacol. Exp. Ther., 2004, 308(1), 307-316.
139. Han, Y.; Englert, J.A.; Yang, R.; Delude, R.L.; Fink, M.P. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J. Pharmacol. Exp. Ther., 2005, 312(3), 1097-1105.
140. Wondrak, G.T.; Cabello, C.M.; Villeneuve, N.F.; Zhang, S.; Ley, S.; Li, Y.; Sun, Z.; Zhang, D.D. Cinnamoyl-based Nrf2-activators targeting human skin cell photo-oxidative stress. Free Radic. Biol. Med., 2008, 45(4), 385-395.
141. Adams, J.D.; Wang, R.; Yang, J.; Lien, E.J. Preclinical and clinical examinations of Salvia miltiorrhiza and its tanshinones in ischemic conditions. Chin. Med., 2006, 1, 3.
142. Pan, T.L.; Hung, Y.C.; Wang, P.W.; Chen, S.T.; Hsu, T.K.; Sintupisut, N.; Cheng, C.S.; Lyu, P.C. Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics, 2010, 10(5), 914-929
143. Lee, C.Y.; Sher, H.F.; Chen, H.W.; Liu, C.C.; Chen, C.H.; Lin, C.S.; Yang, P.C.; Tsay, H.S.; Chen, J.J. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol. Cancer Ther., 2008, 7(11), 3527-3538.
144. Jang, S.I.; Kim, H.J.; Kim, Y.J.; Jeong, S.I.; You, Y.O. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur. J. Pharmacol., 2006, 542(1-3), 1-7.
145. Chiu, Y.C.; Lin, C.Y.; Chen, C.P.; Huang, K.C.; Tong, K.M.; Tzeng, C.Y.; Lee, T.S.; Hsu, H.C.; Tang, C.H. Peptidoglycan enhances IL-6 production in human synovial fibroblasts via TLR2 receptor, focal adhesion kinase, Akt, and AP-1- dependent pathway. J. Immunol., 2009, 183(4), 2785-2792.
146. Zhang, H.S.; Wang, S.Q. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. Biochem. Pharmacol., 2007, 73(9), 1358-1366.
147. Li, W.; Li, J.; Ashok, M.; Wu, R.; Chen, D.; Yang, L.; Yang, H.; Tracey, K.J.; Wang, P.; Sama, A.E.; Wang, H. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J. Immunol., 2007, 178(6), 3856-3864. (Pubitemid 46417655)
148. Fan, G.W.; Gao, X.M.; Wang, H.; Zhu, Y.; Zhang, J.; Hu, L.M.; Su, Y.F.; Kang, L.Y.; Zhang, B.L. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J. Steroid Biochem. Mol. Biol., 2009, 113(3-5), 275-280.
149. Xu, M.; Dong, M.Q.; Cao, F.L.; Liu, M.L.; Wang, Y.X.; Dong, H.Y.; Huang, Y.F.; Liu, Y.; Wang, X.B.; Zhang, B.; Zhao, P.T.; Luo, Y.; Niu, W.; Cui, Y.; Li, Z.C. Tanshinone IIA reduces lethality and acute lung injury in LPS-treated mice by inhibition of PLA2 activity. Eur. J. Pharmacol., 2009, 607(1-3), 194-200.
150. Kim, D.H.; Jeon, S.J.; Jung, J.W.; Lee, S.; Yoon, B.H.; Shin, B.Y.; Son, K.H.; Cheong, J.H.; Kim, Y.S.; Kang, S.S.; Ko, K.H.; Ryu, J.H. Tanshinone congeners improve memory impairments induced by scopolamine on passive avoidance tasks in mice. Eur. J. Pharmacol., 2007, 574(2-3), 140-147.
151. Sha, M.; Yin, L.F.; Xu, W.; Chen, Y.Z. [Effects of 2-n-nonyl-1,3- dioxolane as an enhanceron transdermal absorption of Salvia miltiorrhiza gel]. Zhongguo Zhong Yao Za Zhi, 2007, 32(6), 487-489.
152. Li, W.; Ashok, M.; Li, J.; Yang, H.; Sama, A.E.; Wang, H. A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS. One, 2007, 2(11), e1153. (Pubitemid 351597638)
153. Tang, D.; Kang, R.; Xiao, W.; Zhang, H.; Lotze, M.T.; Wang, H.; Xiao, X. Quercetin prevents LPS-induced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell Mol. Biol., 2009, 41(6), 651-660.
154. Jagtap, S.; Meganathan, K.; Wagh, V.; Winkler, J.; Hescheler, J.; Sachinidis, A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr. Med. Chem., 2009, 16(12), 1451-1462.
155. Lambert, J.D.; Kim, D.H.; Zheng, R.; Yang, C.S. Transdermal delivery of (-)-epigallocatechin-3-gallate, a green tea polyphenol, in mice. J. Pharm. Pharmacol., 2006, 58(5), 599-604.
156. Jones, D.T. Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol., 1999, 292(2), 195-202. (Pubitemid 29435759)